Seeking Alpha
17 Nov 2026, 13:53 UTC · 58m ago
Legend Biotech: The Market Is Missing The Bigger Picture
Impact · against what's priced in
The upcoming mid-December LB2501 data provides a fresh catalyst for LEGN, while the Carvykti sales growth is largely redundant for JNJ. LEGN represents a potential valuation re-rating opportunity if clinical results maintain their high efficacy, whereas JNJ's price already factors in the blockbuster's expansion.
- JNJ+0.00
Already priced in
- The price assumes
The continued double-digit expansion of CARVYKTI toward its $5 billion peak sales target
The 8.1% quarter-on-quarter growth of Carvykti to $710 million aligns with the market's existing assumption of the drug's trajectory toward peak sales.
What JNJ's price assumes · Sep 3





